Mylan - best known for jacking up the price of the EpiPen and misclassifying it to underpay Medicaid rebates - is perpetuating big pharma's stereotype of unscrupulous behavior. This week, they settled in court for a fraction of the money they made through their scheme that bilked both their customers and the government.
